


**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of

**Florence Bordon-Pallier, et al**Application No.: **10/606,424**Filed: **June 26, 2003**Title: **Novel Purine Derivatives, Preparation  
Method and Use as Medicines**Examiner: **To Be Assigned**Art Unit: **1614****TELEFAX CERTIFICATE**

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, 703-746-4060 on

**November 12, 2003**

Date of Transmission  
Bonnie Stein  
Signature 

**LATE SUBMISSION OF DECLARATION  
UNDER 37 C.F.R. 1.53(f)**


Mail Stop Missing Parts  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

In response to the "NOTICE TO FILE MISSING PARTS OF APPLICATION - FILING DATE GRANTED" which was mailed on November 5, 2003 and which indicated that the oath or declaration was missing, Applicants submit herewith the Declaration for the present application and a copy of Form PTO-1533.

Also, enclosed is the Power of Attorney for Patent Application.


Please charge the \$130.00 fee involved to Deposit Account No. 18-1982. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

  
✓ Irving Newman, Reg. No. 22,638  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-2785  
Telefax (908) 231-2626

Docket No. 2541US CNT



12.2003 10:59AM

AVENTIS US PAT DEPT

NO. 4219 P. 3

UNITED STATES OF AMERICA

## DECLARATION FOR PATENT APPLICATION

As a below named inventor(s), I/We hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s). I/We verify believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

### Novel Purine Derivatives, Preparation Method and Use as Medicines

and the specification of which  is attached hereto (Aventis Docket No. 2541US CNT)  
(check one)  was filed on 26 June 2003 as U.S. Application Number 10/606,424  
and was amended on \_\_\_\_\_ (if applicable).  
 was described and claimed in PCT Int'l Application Number \_\_\_\_\_ filed on \_\_\_\_\_  
and as amended under PCT Article 19 on \_\_\_\_\_ (if any).

I/We hereby state that I/We have reviewed and understand the contents of the above identified specification, including the claims as amended by any amendment referred to above. I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 C.F.R. 1.56.

I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one other country other than the United States of America, listed below and having a filing date before that of the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Foreign Priority: 00/17009 France 26 December 2000  
Number Country Day/Month/Year Filed

Prior Foreign Appn(s): PCT/FR01/04051 France 19 December 2001  
Number Country Day/Month/Year Filed

I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional application(s) listed below:

Number Filing Date

I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States application(s) or international application designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Application Serial No. Filing Date Status (Patented, Pending)

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States code §1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventors(s):  Additional names and signatures are attached.

1. Full name: Florence BORDON-PALLIER

Signature: 

Date: 25/07/03


Country of Citizenship: France

Residence: Guyancourt, France

(City and State/City and Country only)

P. O. Address: 37, Boulevard Beethoven  
78280 Guyancourt, FRANCE

2. Full name: Jean-Luc HAESSLEIN

Signature: 


Date: 31/07/2003

Country of Citizenship: France

Residence: Country, France

(City and State/City and Country only)

P. O. Address: 72, Rue du Général de Gaulle  
77181 Country, France



## PATENT

Aventis Docket No. 2541US CNT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEApplicants: **Florence Bordon-Pallier, et al**

Examiner: To Be Assigned

Serial No.: **10/606,424**

Group Art Unit.: To Be Assigned


Filed: **June 26, 2003**Title: **Novel Purine Derivatives, Preparation Method and Use as Medicines**POWER OF ATTORNEY FOR PATENT APPLICATION

Mail Stop Missing Parts  
 Commissioner of Patents  
 P. O. Box 1450  
 Alexandria, VA 22313-1450

Dear Sir:

I, F. David, an Authorized Signatory of Aventis Pharma S.A., Assignee of the above-identified Application, hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as attorneys and/or agents with full power to prosecute this application on behalf of Assignee and to transact all of Assignee's business in connection with the above-identified Application in the Patent and Trademark Office:

Customer Number:

Effective Date: June 26, 2003

By: \_\_\_\_\_

Title: François DAVID  
FONDE DE POUVOIRDate: August 4, 2003

Address correspondence and telephone calls to:

Irving Newman, Reg. No. 22,638  
 Aventis Pharmaceuticals Inc.  
 Patent Department  
 Route #202-206 / P.O. Box 6800  
 Bridgewater, New Jersey 08807-0800  
 Telephone (908) 231-2785  
 Telefax (908) 231-2626